Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUSTAIN: daclizumab after natalizumab switch in RRMS
2016-002820-10Phase 3Completed
- Sponsor
- Biogen
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of daclizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Primary endpoint: Proportion of participants relapse-free at Month 6. Started Nov 2016; status: completed.
02
Drugs
daclizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2016-002820-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002820-10.